BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports Initiation Of ZENITH-1

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) reported the dosing of the first subject into its clinical study of ZENITH-1. This study is assessing up to 3 dosage strengths of BCX7353 administered as a single oral dose targeting acute treatment of angioedema attacks in people with hereditary angioedema. The details Jon Stonehouse, the Chief Executive Officer of BioCryst, […]

Ebola Fears: Drug And Suit Makers Up In The Market

Boston, MA 10/13/2014 (wallstreetpr) – The Ebola menace is slowly finding its way in the U.S. after a nurse who cared for an Ebola patient was also diagnosed with the virus. Companies developing cures for the diseases lead by Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) and Sarepta Therapeutics Inc. (NASDAQ:SRPT) have been on an upward swing. Focus […]

Investors Eye Sumptuous Retuns From BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX’s) Recent Endeavors

Boston, MA 10/06/2014 (wallstreetpr) – BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) revealed in a declarative statement that the prestigious National Institute of Allergy and Infectious Diseases, dubbed as NIAID, has aptly practiced two options that provides manufacture of the product – BCX4430 and another GMP drug substance. If these options are duly exercised, it would lead to a […]

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports RAPIVAB Trial Results At The ICAAC 2014 Meeting

Boston, MA 09/08/2014 (wallstreetpr) – According to reports, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) recently announced the trial results of peramivir injection (RAPIVAB). It is a neuraminidase inhibitor for the treatment of influenza. BCRX finished the study some time back, and it decided to reveal the final trial results on the special occasion of ICAAC (the Inter-Science […]

Cardiome Pharma Corporation (NASDAQ:CRME) Stock Moves Higher; Performance Better Than Some Competitors

Boston, MA 03/06/2014 (wallstreetpr) – Cardiome Pharma Corporation (NASDAQ:CRME) stock surged higher by 27% in the last four weeks. The stock is performing better than its 20 day Simple Moving Average. While analysts at Zacks see the trend as a good one and expect investors to be happy with the company’s short term performance, they […]

Biocryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Edges Closer To Marburg Virus Treatment

Boston, MA 03/06/2014 (wallstreetpr) – Biocryst Pharmaceuticals, Inc. (NASDAQ:BCRX) now deserves increased attention from investors if that was not there already. The company just published a medical research report that all but suggests that it could crack Marburg virus. And that could mean massive gains for the company and its investors if the drug it […]

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is An Appealing Investment For Long Run

Boston, MA 07/22/2013 (wallstreetpr) – The biotechnology business has always appealed to investors seeking the best home run investment. One niche within that business that looks balanced to augment deals with small molecule medicines used to cure illnesses. With hoards of money being invested into this section on a yearly basis, the stakes are high but […]

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s shares recording significant gains

Boston, MA 07/12/2013 (wallstreetpr) – Shares of biotechnology companies have been recording significant gains for the past few trading sessions. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), with a primary focus on the development and commercialization of drugs aimed at blocking the enzymes involved in the pathogenesis of diseases, has recently been experiencing significant surges supported by huge trading […]